R59- GERN, thanks
Appreciate your view. I personally believe that Imetelstat will do better than most think. Most importantly, GERNs Imetelstat treats ringed(25%) and un ringed(75%) sideroblasts cell types in low risk MDS equally effecitvely, where as Bristol Myers Reblozyl treats only ringed sideroblasts effectively. There is an article off Google that states this should be an egde for GERN. So maybe, even though Reblozyl has FDA first line status, GERN will definitely be recognized as a major alternative. I mean GERN and Bristol Myers will be sharing an approximate $5B+/year worldwide market by 2030. I don't see how GERN won't eventually get at least $1B/year of that, which would make the stock worth at least $10 IMO.
